Abbott’s Bioresorbable Stent Shows Durable Results In ABSORB Trial
This article was originally published in The Gray Sheet
Latest clinical results for Abbott’s Absorb Bioresorbable Vascular Scaffold show the disappearing stent actually increases the space inside the stented vessel segment over time. The company’s efforts to launch a pivotal randomized trial of the device are hindered by FDA, according to the lead investigator.
You may also be interested in...
This year’s Transcatheter Cardiovascular Therapeutics meeting featured several presentations of favorable new data on Abbott’s Absorb bioresorbable vascular scaffold. The company is optimistic that it will be able to complete a PMA application to FDA for the disappearing stent by the end of 2015.
New cancer companion diagnostic approved. Biotronik’s Ilesto 7 ICD and CRT-D earns FDA approval. More new product announcements.
Reva launches bioresorbable stent trial. Meta-analysis shows tests intended simply to reassure patients rarely do. Sorin launches trial of the SonR cardiac resynchronization system.